Drug intelligence / Profile preview

Tiandan Tongluo

Development stage: Unknown
Lead developer: Guangdong Provincial Hospital of Traditional Chinese Medicine
Administration: Oral

Overview

Tiandan Tongluo is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, developed for the treatment of cerebral infarction (ischemic stroke) during the recovery period. It is specifically indicated for patients exhibiting TCM patterns of meridian obstruction, wind-phlegm, and blood stasis. The formulation aims to improve neurological function and promote recovery by addressing these underlying pathological patterns. It is currently being evaluated in clinical trials sponsored by the Guangdong Provincial Hospital of Traditional Chinese Medicine to assess its efficacy and safety in post-stroke rehabilitation.

Brand names: Tiandan Tongluo Capsule
Other names: Tiandan Tongluo CapsuleTiandan Tongluo Jiaonang

Beyond the preview

Go deeper on Tiandan Tongluo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tiandan Tongluo.

Explore the full profile